BlossomHill Therapeutics, Inc. (BLSM) News
Follow BlossomHill Therapeutics, Inc. (BLSM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BlossomHill Therapeutics, Inc. (BLSM) Reports Preclinical Data on Pan-KRAS BH-501284
BlossomHill Therapeutics presented preclinical data for BH-501284, a non-covalent pan-KRAS inhibitor, showing sustained KRAS pathway suppression and antitumor activity, and said it supports an IND submission planned for
NEWS | Sep 28, 2026, 11:09 AM UTC
L
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027
NEWS | Sep 28, 2026, 11:08 AM UTC
M
BlossomHill Therapeutics reports Q2 net loss and upsized IPO
BlossomHill Therapeutics reported a Q2 2026 net loss of $23.8M, ended June with $95.4M cash, and raised $168.3M gross in an upsized IPO. The company expects cash to fund operations into Q2 2028.
EQUITY | Sep 18, 2026, 11:02 AM UTC
L
BLSM - BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
BLSM - BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
EARNINGS | Sep 18, 2026, 11:01 AM UTC
M
BlossomHill Therapeutics reports 2Q loss of $23.8M
BlossomHill Therapeutics reported a 2Q loss of $23.8M.
EARNINGS | Sep 18, 2026, 11:01 AM UTC
L
BLSM: Lead EGFR inhibitor shows durable responses in resistant cancer, with pivotal milestones ahead
BlossomHill presented strong phase I data for its lead EGFR inhibitor, showing high response rates and durability in C797S-resistant patients, with a favorable safety profile and differentiation from competitors. Key mil
NEWS | Sep 15, 2026, 03:40 PM UTC
L
BLSM: Lead EGFR inhibitor shows high efficacy and durability in resistant cancers, with key milestones ahead
BlossomHill presented strong clinical data for its lead EGFR inhibitor, showing high response rates and durability in resistant cancer populations, with a favorable safety profile and clear differentiation from competito
NEWS | Sep 15, 2026, 03:21 PM UTC
L
BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned
BlossomHill reported a 45% objective response rate and 88% disease control rate for BH-30643 in EGFR C797S-positive NSCLC.Key Highlights:Original SEC Filing: BlossomHill Therapeutics, Inc. [ BLSM ] - 8-K - Sep. 15, 2026T
CENTRAL_BANK | Sep 15, 2026, 11:33 AM UTC
L
BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti- Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S- Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti- Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S- Positive NSCLC at IASLC 2026 World
NEWS | Sep 15, 2026, 11:00 AM UTC
L
BlossomHill Therapeutics to present at RAS summit and H.C. Wainwright conference
BlossomHill Therapeutics, Inc. said it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
BLSM - BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Inves
BLSM - BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 03, 2026, 11:00 AM UTC
M
LifeSci Capital initiates BlossomHill Therapeutics at Outperform
LifeSci Capital initiated BlossomHill Therapeutics with an Outperform rating and set a $32.00 price target per share, per Benzinga via TradingView News.
EQUITY | Sep 01, 2026, 06:59 PM UTC
L
Leerink Partners starts BlossomHill Therapeutics at Outperform, $36 target
Leerink Partners initiated coverage on BlossomHill Therapeutics with an Outperform rating and announced a $36.00/share price target.
EQUITY | Sep 01, 2026, 06:50 PM UTC
L
JP Morgan sets $28 price target for BlossomHill Therapeutics
JP Morgan announced a $28.00/share price target for BlossomHill Therapeutics.
EQUITY | Sep 01, 2026, 12:59 PM UTC
L
Guggenheim sets $30 price target on BlossomHill Therapeutics
Guggenheim announced a $30.00 per share price target for BlossomHill Therapeutics.
EQUITY | Sep 01, 2026, 12:39 PM UTC
L
BlossomHill to present updated Phase 1/2 SOLARA trial data
BlossomHill Therapeutics will present updated Phase 1/2 SOLARA trial data for BH-30643, its macrocyclic OMNI-EGFR inhibitor, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.
REGULATION | Sep 01, 2026, 11:08 AM UTC
L
BLSM to present updated SOLARA Phase 1/2 trial data
BlossomHill Therapeutics will present updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.
EQUITY | Sep 01, 2026, 11:01 AM UTC
L
HC Wainwright & Co. sets $35.00 price target for BlossomHill
HC Wainwright & Co. announced a $35.00 per-share price target for BlossomHill Therapeutics, according to ratings actions reported by Benzinga via TradingView News.
EQUITY | Sep 01, 2026, 10:42 AM UTC
H
BlossomHill Therapeutics gets FDA Fast Track for BH-30643 in EGFR C797S+ NSCLC
BlossomHill Therapeutics announces the FDA grants Fast Track designation to BH-30643, its macrocyclic OMNI-EGFR™ inhibitor, for treating advanced EGFR C797S-positive NSCLC.
REGULATION | Aug 18, 2026, 11:00 AM UTC